Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05498428 · ClinicalTrials.gov registry record · Phase 2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
520
Enrollment target
20
Study locations

NCT05498428 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 520 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05498428, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
520 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG Amivantamab
  • DRUG Lazertinib
  • DRUG Direct Oral Anticoagulant (DOAC)

Study Locations (20)

Florida

  • Baptist Lynn Cancer Institute - Boca Raton
  • Mount Sinai Medical Center - Miami Beach
  • AdventHealth - Orlando
  • H. Lee Moffitt Cancer & Research Institute - Tampa

California

  • University of California at San Diego - La Jolla
  • University of California Irvine - Orange
  • Stanford Cancer Institute - Stanford

Ohio

  • Cleveland Clinic - Cleveland
  • Cleveland Clinic - Cleveland
  • Cleveland Clinic - Mayfield Heights

New Jersey

  • Hackensack University Medical Center - Hackensack
  • Rutgers Cancer Institute of New Jersey - New Brunswick

North Carolina

  • Novant Health - Charlotte
  • Novant Health - Winston-Salem

District of Columbia

  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital - Washington D.C.

Kansas

  • University of Kansas Cancer Center - Westwood

Maryland

  • Sidney Kimmel Cancer Center - Bayview Campus - Baltimore

Trial Details

FieldValue
Enrollment Target 520 participants
Start Date 2022-11-11
Est. Completion 2028-08-18
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05498428

The ClinicalTrials.gov registry entry for NCT05498428 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (63% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05498428 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT05498428 about?

NCT05498428 is a clinical study titled "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer". The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characteri...

What is the current status of trial NCT05498428?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 520 participants. The study started on 2022-11-11. Estimated completion is 2028-08-18.

What conditions does trial NCT05498428 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT05498428?

The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Amivantamab (DRUG), Lazertinib (DRUG), Direct Oral Anticoagulant (DOAC) (DRUG).

Who is sponsoring clinical trial NCT05498428?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05498428 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.